A Phase 3 interventional study of Amrubicin Hydrochloride and Etoposide-Cisplatin combined chemotherapy in Lung Cancer, sponsored by Sumitomo Pharma (Suzhou) Co., Ltd.. Completed at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-18.
Sponsored by Sumitomo Pharma (Suzhou) Co., Ltd. (formerly part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 844 studies in Lung Neoplasms with a site in China — 371 open to participants now, 418 under way, 34 of them phase 3. Lung Neoplasms · China.
Among the 844 studies in Lung Neoplasms with a site in China, this one is the 108th largest by enrollment of the 585 interventional ones that give a count, is one of 6 that started in 2008, is one of 66 in phase 3, and was the 14th registered.
5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →371 of the 844 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:
Zhongnan Hospital · Sites in China
Ages 18+ · Healthy volunteers
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
West China Hospital · Sites in China
Ages 18–80
Xiamen University · Sites in China
Ages 18–80
AstraZeneca · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
844 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 137 · Phase 2 225 · Phase 3 77 · Phase 4 9
First in 1992; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 60 across 3,657 interventional studies indexed under Lung Neoplasms.
Median enrollment 90 across the 585 interventional studies, 304 across the 258 observational. Of the 207 that completed or were terminated, 36 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
185 of 844 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma (Suzhou) Co., Ltd., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma (Suzhou) Co., Ltd. is the lead sponsor of 13 studies on the registry; none are open to participants now.
Sumitomo Pharma Co., Ltd. has 3 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
117 of the studies in Lung Neoplasms with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607796Phase 3Zhou ChengzhiEfficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy | 2026-12 |
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT04841811Phase 3Guangdong Association of Clinical TrialsMDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH) | 2026-12-31 |
| NCT06598527Phase 3Yang HongStereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study | 2027-01-30 |
Add all 117 to your calendar (.ics) → With an account.
Among the 844 studies in Lung Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study drug(Amrubicin)is believed to work by stopping the tumor cell in your body from growing. The purpose of this study is to evaluate the efficacy and safety of amrubicin with cisplatin compared to etoposide-cisplatin in the first-line treatment in extensive disease small cell lung cancer The subject, who is randomized to AP group may be involved into a pharmacokinetic study of amrubicin and the metabolites: amrubicinol voluntarily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Amrubicin Hydrochloride-Cisplatin combined chemotherapy
Drug: Amrubicin Hydrochloride
Etoposide-Cisplatin combined chemotherapy
Drug: Etoposide-Cisplatin combined chemotherapy
Amrubicin Hydrochloride combined with cisplatin
combined chemotherapy
Overall Survival
Time frame: 1.5 years after last subject enrolled
Progression-Free Survival
Time frame: 1.5 years after last subject enrolled
Objective Response Rate
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: participants were followed for the duration of the study, an average of 12 weeks
Overall Survival at 6 and 12 Months
Time frame: 6 and 12 months.
| Milestone | Amrubicin Combined With Cisplatin Group | Etoposide Combined With Cisplatin Group |
|---|---|---|
| Started | 149 | 151 |
| Completed | 149 | 150 |
| Not completed | 0 | 1 |
| month | Amrubicin Combined With Cisplatin Group | Etoposide Combined With Cisplatin Group |
|---|---|---|
| Overall Survival | 11.79 (11.01 to 12.62) | 10.28 (9.23 to 11.96) |
| percentage of patients | Amrubicin Combined With Cisplatin Group | Etoposide Combined With Cisplatin Group |
|---|---|---|
| 6-month | 89.26 (83.07 to 93.28) | 86.00 (79.34 to 90.64) |
| 12-month | 48.59 (40.31 to 56.36) | 41.93 (33.97 to 49.68) |
| month | Amrubicin Combined With Cisplatin Group | Etoposide Combined With Cisplatin Group |
|---|---|---|
| Progression-Free Survival | 6.83 (6.11 to 7.39) | 5.72 (5.06 to 6.93) |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| percentage of participants | Amrubicin Combined With Cisplatin Group | Etoposide Combined With Cisplatin Group |
|---|---|---|
| Objective Response Rate | 69.80 | 57.33 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Amrubicin, Anticancer, Injection | — | 21/149 (14.1%) | 149/149 (100%) |
| Etoposide, Anticancer, Injection | — | 8/150 (5.3%) | 148/150 (98.7%) |
| Event | Amrubicin, Anticancer, Injection | Etoposide, Anticancer, Injection |
|---|---|---|
| Neutrophil count decreasedInvestigations | 7/149 | 0/150 |
| White blood cell count decreasedInvestigations | 6/149 | 0/150 |
| Bone marrow failureBlood and lymphatic system disorders | 5/149 | 3/150 |
| Febrile neutropenia syndromeBlood and lymphatic system disorders | 3/149 | 0/150 |
| Platelet count decreasedInvestigations | 3/149 | 1/150 |
| DiarrheaGastrointestinal disorders | 2/149 | 0/150 |
| feverInfections and infestations | 2/149 | 0/150 |
| HypokalemiaMetabolism and nutrition disorders | 2/149 | 0/150 |
| Cerebral infarctionNervous system disorders | 1/149 | 2/150 |
| AgranulocytosisBlood and lymphatic system disorders | 1/149 | 0/150 |
| Event | Amrubicin, Anticancer, Injection | Etoposide, Anticancer, Injection |
|---|---|---|
| Neutrophil count decreasedBlood and lymphatic system disorders | 99/149 | 85/150 |
| White blood cell count decreasedBlood and lymphatic system disorders | 97/149 | 85/150 |
| NauseaGastrointestinal disorders | 72/149 | 70/150 |
| vomitGastrointestinal disorders | 63/149 | 63/150 |
| Decreased appetiteGastrointestinal disorders | 60/149 | 50/150 |
| Platelet count decreasedBlood and lymphatic system disorders | 54/149 | 40/150 |
| Lower hemoglobinBlood and lymphatic system disorders | 49/149 | 50/150 |
| AnemiaBlood and lymphatic system disorders | 48/149 | 48/150 |
| Bone marrow failureBlood and lymphatic system disorders | 46/149 | 46/150 |
| ConstipationGastrointestinal disorders | 32/149 | 25/150 |
| Age, Continuous(years) | Amrubicin, Anticancer, Injection | Etoposide, Anticancer, Injection | Total |
|---|---|---|---|
| Mean | 56.1 ± 10.03 | 57.45 ± 9.78 | 56.78 ± 9.92 |
| Sex: Female, Male(Participants) | Amrubicin, Anticancer, Injection | Etoposide, Anticancer, Injection | Total |
|---|---|---|---|
| Female | 35 | 37 | 72 |
| Male | 114 | 113 | 227 |
| Region of Enrollment(participants) | Amrubicin, Anticancer, Injection | Etoposide, Anticancer, Injection | Total |
|---|---|---|---|
| China | 149 | 150 | 299 |
The record gives a start of Apr 2008, a primary completion of Feb 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amrubicin
Sumitomo Pharma (Suzhou) Co., Ltd. →